Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATX NYSE:FTT CVE:HEM CVE:NSCI CVE:PAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXCosta$2,934.88$0.00▼$0.00N/AN/AN/AN/AFTTFederated Enhanced Treasury Income Fund$0.00$12.81▼$13.82N/AN/A24,050 shsN/AHEMHemostemixC$0.10-13.0%C$0.11C$0.06▼C$0.43C$18.11M1.193301374,976 shs608,237 shsNSCINanalysis ScientificC$0.19-2.6%C$0.23C$0.18▼C$0.41C$21.24M-0.87393484,441 shs209,535 shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXCosta0.00%0.00%0.00%0.00%0.00%HEMHemostemix-13.04%-20.00%+25.00%-20.00%+17.65%NSCINanalysis Scientific-2.63%-11.90%-19.57%-26.00%-44.78%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXCosta$2,934.88$0.00▼$0.00N/AN/AN/AN/AFTTFederated Enhanced Treasury Income Fund$0.00$12.81▼$13.82N/AN/A24,050 shsN/AHEMHemostemixC$0.10-13.0%C$0.11C$0.06▼C$0.43C$18.11M1.193301374,976 shs608,237 shsNSCINanalysis ScientificC$0.19-2.6%C$0.23C$0.18▼C$0.41C$21.24M-0.87393484,441 shs209,535 shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXCosta0.00%0.00%0.00%0.00%0.00%HEMHemostemix-13.04%-20.00%+25.00%-20.00%+17.65%NSCINanalysis Scientific-2.63%-11.90%-19.57%-26.00%-44.78%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXCosta 0.00N/AN/AN/AFTTFederated Enhanced Treasury Income Fund 0.00N/AN/AN/AHEMHemostemix 0.00N/AN/AN/ANSCINanalysis Scientific 0.00N/AN/AN/APASPascal Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXCostaN/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/ANSCINanalysis ScientificC$43.03M0.49C$0.02 per share8.93C$0.21 per share0.88PASPascal BiosciencesN/AN/AC$0.00 per share55.00C($0.02) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXCostaN/AN/A0.00N/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/A0.00N/AN/AN/AN/AN/AN/AHEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/ANSCINanalysis Scientific-C$12.93M-C$0.11N/A∞N/A-32.75%-38.02%-7.55%N/APASPascal BiosciencesN/A-C$0.01N/A∞N/AN/AN/A-340.40%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXCostaN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/ANSCINanalysis ScientificN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXCostaN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AHEMHemostemix-55.070.040.48NSCINanalysis Scientific71.721.421.11PASPascal Biosciences882.790.030.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXCostaN/AFTTFederated Enhanced Treasury Income FundN/AHEMHemostemixN/ANSCINanalysis Scientific0.03%PASPascal BiosciencesN/AInsider OwnershipCompanyInsider OwnershipATXCostaN/AFTTFederated Enhanced Treasury Income FundN/AHEMHemostemix10.43%NSCINanalysis Scientific3.95%PASPascal Biosciences15.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXCostaN/AN/AN/ANot OptionableFTTFederated Enhanced Treasury Income FundN/AN/AN/ANot OptionableHEMHemostemixN/A181.05 millionN/ANot OptionableNSCINanalysis Scientific249114.82 millionN/ANot OptionablePASPascal Biosciences665.59 millionN/ANot OptionableHEM, NSCI, ATX, FTT, and PAS HeadlinesRecent News About These CompaniesPascal AI Raises $3.1 Million to Accelerate Autonomous Investment Research WorkflowsSeptember 15 at 8:05 AM | finance.yahoo.comThe Original Calculator? Blaise Pascal’s Mechanical Marvel Could Fetch Millions at AuctionSeptember 13 at 10:24 AM | news.artnet.comNActor Pedro Pascal takes Pedro Piscal brand brandy to court in ChileSeptember 12, 2025 | msn.comPedro Pascal's future as The Mandalorian's Din Djarin just got a big updateSeptember 11, 2025 | msn.comPedro Pascal supports Sabrina Carpenter after trans rights performance at MTV VMAsSeptember 10, 2025 | msn.comTom Cruise Upset With Pedro Pascal Getting More Attention, Says SourceSeptember 9, 2025 | yahoo.comIs Tom Cruise upset about his agency's focus on Pedro Pascal? Here's what we knowSeptember 9, 2025 | msn.comTom Cruise Upset With Agency Giving Pedro Pascal More Attention, Says SourceSeptember 9, 2025 | yahoo.comPedro Pascal Tipped To Replace Joaquin Phoenix In Steamy Gay RomanceAugust 28, 2025 | yahoo.comPedro Pascal in talks to play the lead in De Noche: Here’s all you need to know about the Todd Haynes filmAugust 28, 2025 | soapcentral.comSPedro Pascal in Talks to Star in Todd Haynes' Gay Romance Film After Joaquin Phoenix's Abrupt ExitAugust 28, 2025 | msn.comPascal and Treehouse Partner on Proof of Concept to Pioneer Smart Clearing for Decentralized Fixed Income ProductsAugust 27, 2025 | financial-news.co.ukPedro Pascal Was a Superhero Long Before 'Fantastic Four' in This Hit Netflix Movie That Dominated StreamingAugust 22, 2025 | collider.comCPedro Pascal’s Most Intense Role Still Haunts Fans—Long Before Helmets & Superpowers Took Over!August 5, 2025 | koimoi.comKPedro Pascal Guessed Joseph Quinn’s Go-To Sandwich & Now We Know What We're Getting For LunchAugust 5, 2025 | aol.comAGeneral Hospital’s Kelly Thiebaud on Why Britt & Pascal Will ‘Butt Heads’August 5, 2025 | yahoo.comPedro Pascal at the Fantastic Four Premiere: Did We Get Close?August 5, 2025 | msn.comMaking 'Last of Us' without Pedro Pascal was tough. But Bella Ramsey loves a challengeAugust 5, 2025 | msn.comnVidia launches Pascal graphics for laptopsJuly 20, 2025 | msn.comPedro Pascal’s Stylist Exits After Claiming She Received Death Threats Over One Of His OutfitsJuly 20, 2025 | yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Time to Take Profits on Strategy Stock? 3 Reasons You ShouldBy Gabriel Osorio-Mazilli | September 1, 2025Ozempic Boom: Hims & Eli Lilly Lead Healthcare BetsBy Gabriel Osorio-Mazilli | August 21, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025Ride the Luxury Retail Wave with These 3 High-End Brand StocksBy Dan Schmidt | September 13, 2025HEM, NSCI, ATX, FTT, and PAS Company DescriptionsCosta NASDAQ:ATXCosta Inc, formerly A. T. Cross Company is a designer and marketer of branded personal accessories, including writing instruments, reading glasses, personal and business accessories and sunglasses. The Company's Cross Optical Group (COG) consists of its wholly owned subsidiary, Cross Optical Group, Inc. and is the legal entity of the Company's two sunglass brands: Costa and Native. The Company's COG designs, manufactures and markets polarized sunglasses under the brand names Costa and Native. The Company's brands offer sunglasses in more than 75 styles and 25 lens options. In September 2013, the Company sold its Cross Accessory Division and the rights to the A.T. Cross name, which was associated with the writing instrument business. Effective February 3, 2014, Essilor International SA acquired Costa Inc.Federated Enhanced Treasury Income Fund NYSE:FTTFederated Premier Intermediate Municipal Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is to provide current income exempt from federal income tax, including the federal alternative minimum tax (AMT). The Fund's portfolio of investments include various sectors namely transportation, special tax, hospital, education, public power, senior care, water and sewer, general obligation-local, industrial development bond/pollution control revenue and general obligation-state. The Fund invests in intermediate-term, tax-exempt municipal bonds diversified among states, sectors and issuers. Federated Investment Management Company is the advisor of the Fund.Hemostemix CVE:HEMC$0.10 -0.02 (-13.04%) As of 09/15/2025 03:59 PM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.Nanalysis Scientific CVE:NSCIC$0.18 -0.01 (-2.63%) As of 09/15/2025 03:59 PM EasternNanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.Pascal Biosciences CVE:PASC$0.02 -0.01 (-25.00%) As of 12/5/2022Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
